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Abstract 
Infection with human papillomavirus (HPV), the sexually transmitted virus that causes cervical 
and other types of cancer, can be prevented. A safe and effective vaccine has been approved for 
both boys and girls. Despite this recommendation and alarming rates of HPV-associated cancers, 
vaccination rates among adolescents in the United States are low. A capstone project was 
implemented to target students and parents of students who attend Holyoke High School and 
William J. Dean Vocational Technical High (Dean Tech) in Holyoke, Massachusetts. The goals 
of the project were to improve knowledge about HPV and the HPV vaccine in students and 
parents, to increase the number of parents of adolescents who intend to vaccinate their children 
against HPV, and to increase the number of adolescents who intend to receive the HPV vaccine. 
The project was based on the theoretical framework of the Health Belief Model. Students in 
ninth grade health classes at both schools were taught content about HPV and why they should 
receive the HPV vaccine. An informational handout was sent home with all ninth grade students 
at the schools and reminded them that the school-based health center (SBHC) had the HPV 
vaccine available. Outreach to parents was done at two community events. The research 
translation method that was used for this project is an educational intervention that utilized the 
Plan-Do-Study-Act (PDSA) model. Evaluation of this project was done with a pre-test post-test 
design with the ninth grade students. The results showed an increase in knowledge and increase 
in intent among the students to get vaccinated against HPV. No formal data was gathered from 
the parents. Knowledge gained from this capstone project should encourage nurses to continue 
educating adolescents and their parents about the HPV vaccine and showed that SBHCs are a 
promising site to increase HPV vaccination rates.  
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Increasing Knowledge About HPV and the HPV Vaccine Amongst Adolescents and Adults 
Through a School-Based Setting: A Capstone Project  
 In June of 2006, the United States (U.S) Food and Drug Administration (FDA) released a 
statement that the vaccine Gardasil® had been approved for use to prevent four types of human 
papillomavirus (HPV) that can cause cervical, vaginal, and vulvar cancer and genital warts in 
women (U.S. FDA, 2006). This was groundbreaking medical news. Headlines around the world 
announced the news of the first ever vaccine to prevent cancer (British Broadcast Company, 
2006; Harris, 2006; Rubin, 2006). Another vaccine, Cervarix®, was released in 2009. Cervarix® 
prevents two types of HPV that can cause cervical cancer and precancerous lesions (U.S. FDA, 
2009).  
 There are many types of cancer that are related to HPV. According to the Centers for 
Disease Control and Prevention (CDC) (2011a), almost all cases of cervical cancer are caused by 
HPV. Ninety percent of anal cancers, 65% of vaginal cancers (De Vuyst, Clifford, Nascimento, 
Madeleine, & Franceschi, 2008), 50% of vulvar cancers, 35% of penile cancers (Parkin & Bray, 
2006), and 60% of oropharyngeal cancers (Kreimer, Clifford, Boyle, & Franceschi, 2005) can be 
attributed to HPV infection. The CDC (2012b) estimates that over 20 million Americans are 
infected with HPV and every year there are 6 million new cases of HPV infection.  
 There are over 40 types of HPV virus. Types 16 and 18 are the most oncogenic strains of 
the HPV virus. They are responsible for causing over 70% of cases of cervical cancer and a large 
proportion of other types of genital cancer. HPV types 6 and 11 are responsible for causing over 
90% of cases of genital warts. Cervarix® is a bivalent vaccine that prevents HPV types 16 and 
18. Gardasil® is a quadrivalent vaccine that prevents HPV types 6, 11, 16, and 18 (CDC, 2012b). 
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 The Advisory Committee for Immunization Practices (ACIP) is a group of medical and 
public health experts that are appointed by the Secretary of the U.S. Department of Health and 
Human Services to make recommendations about vaccines for residents of the U.S. (CDC, 
2012a). ACIP first recommended in 2006 that females between the ages of 9-26 be vaccinated 
with Gardasil® to prevent cervical cancer and genital warts (CDC, 2007). In October 2009, 
ACIP recommended that all males between the ages of 9-26 be vaccinated with Gardasil® to 
prevent genital warts (CDC, 2010). In December 2011, ACIP again recommended all males and 
females between the ages of 9-26 be vaccinated with Gardasil® because the vaccine can also 
prevent anal cancer (CDC, 2011b). In 2011, ACIP also recommended that routine HPV 
vaccination begin in males and females starting at age 11, but the vaccine can still be given as 
early as age nine if parents are willing and provide consent. This age is recommended because 
ideally the vaccine should be given before the adolescent has sexual contact for the first time 
(CDC, 2011b). A study published in 2004 by Weinstock, Berman, and Cates Jr. revealed that 
even though youth, ages 15-24, only account for about a quarter of the sexually active population, 
they account for over half of all new sexually transmitted diseases (STDs) in the U.S. each year. 
 The CDC (2012b) predicted that at least 50% of individuals will have been exposed to 
the HPV virus at some point during their lifetime. Approximately 90% of people’s immune 
systems will clear the virus from their body within two years, but for the 10% who are unable to 
clear it, HPV can cause genital warts or types of cancer. This is why vaccination for males and 
females against HPV is important. 
Problem 
 In 2012, it was estimated that 12,170 women would be diagnosed with invasive cervical 
cancer and that 4,220 women would die from the disease in the U.S. (American Cancer Society, 
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2012). Cervical cancer rates have significantly improved over time since the advent of the 
Papanicolaou (Pap) test, but women are still dying from a disease that doctors can effectively 
screen for and now have a preventative vaccine (National Cancer Institute, 2012b). Women of 
color and of lower socioeconomic status are disproportionately affected by cervical cancer. The 
CDC (2012d) reported that Black and Hispanic women have higher rates of cervical cancer than 
white women. From 2004-2008, 9.9/100,000 Black women and 11.3/100,000 Hispanic women 
were diagnosed with cervical cancer compared with 7.4/100,000 white women. It is unclear 
whether the rates are higher due to incidence of disease or because Black and Hispanic women 
have less access to screening and treatment than white women. The National Cancer Institute 
(2012a) reported from 1998 to 2010, women who lived in households with incomes at less than 
200 percent of the poverty level or had not graduated from high school, were less like to have 
had a Pap test. 
 The CDC (2012h) estimated there are about 3,100 new cases of HPV-associated vulvar 
cancer every year in the U.S. From 2004-2008, there were 1.9/100,000 cases in white women 
compared with 1.4/100,000 cases in Black women and 1.2/100,000 cases in Hispanic women. 
There were very few cases of HPV-associated vaginal cancer. The CDC (2012g) estimated there 
are about 740 new cases per year. Black women had the highest rates from 2004-2008 at 0.7 
cases per 100,000 women while white and Hispanic women had 0.4 cases per 100,000 women.  
 HPV-associated penile cancer is also another rare cancer in the U.S. The CDC (2012f) 
estimated there are about 1,000 new cases per year. From 2004-2008, Hispanic men had the 
highest rates at 1.3/100,000 men, compared with 0.7/100,000 in non-Hispanic men. The CDC 
(2012c) estimated there are about 3,000 new cases of HPV-associated anal cancer each year. 
White women and Black men have more cases of anal cancer than women and men of other 
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races. Men are disproportionately affected by HPV-associated oropharyngeal cancer. The CDC 
(2012e) estimated there are 9,356 new cases in men and 2,370 new cases in women every year. 
White and Black men and women have higher rates of oropharyngeal cancer than Hispanic men 
and women. 
 Despite these staggering cancer statistics, the groundbreaking news about the HPV 
vaccine, startling HPV statistics, and the ACIP recommendations, rates of HPV vaccination 
remain the lowest of all adolescent vaccines in the U.S. (Hughes, Jones, Feemster, & Fiks, 2011). 
A report recently released by the CDC (2012j) discussed vaccination rates of males and females, 
ages 13-17. As of 2011, only 34.8% of females and 1.3% of males had received all three doses of 
the HPV vaccine. The rate of females who had received at least one dose of the HPV vaccine 
increased from 48.7% in 2010 to 53% in 2011. Females, ages 14-17, were significantly more 
likely to have received a dose of the vaccine than females under the age of 13.  
 HPV vaccine initiation, in both males and females ages 13-17, was higher for Blacks and 
Hispanics than whites and vaccine completion was higher in Hispanics. Completion of the HPV 
vaccine series was lower in Black females than white females. In both sexes, vaccination rates 
were higher for adolescents living below the poverty line than those living at or above the 
poverty line except that females living below the poverty line had lower vaccine completion rates 
(CDC, 2012i).  
 HPV vaccination rates significantly vary by state. As of 2011, in youth ages 13-17, 
31.9% of females in Mississippi had received at least one dose of the HPV vaccine, compared 
with 76.1% in Rhode Island. Females who had received all three doses of the vaccine were 
lowest in Arkansas at 15.5% as opposed to the highest rates in Rhode Island at 56.8%. In 
Massachusetts (Mass.), 61.1% of females had received at least one dose and 48.5% had received 
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three doses of the HPV vaccine. The rate of males who had received at least one dose in the state 
was 5.8% (CDC, 2012j). One of the goals of Healthy People 2020 is for 80% of girls between 
the ages of 13-15 in the U.S. to have received all three doses of the HPV vaccine (U.S. Dept. of 
HHS, 2012). Currently the U.S. is not on track to reach this goal.  
Review of Literature 
Review of the Evidence  
 An extensive search of the literature was performed to answer the question: how can 
nurses increase knowledge about HPV and the HPV vaccine and increase vaccination rates in 
adolescents? The search was performed in PubMed of the National Library of Medicine and the 
Current Index to Nursing Allied Health Literature (CINAHL). The search terms that were used 
included: “adolescents,” “HPV vaccine,” “HPV,” and “school-based vaccination programs.” The 
following limits were placed in the search: English language, items with abstracts, and free full 
text articles. No time frame was specified due to the fact that HPV vaccination only began in 
2006. Inclusion criteria included articles related to increasing HPV vaccination rates in 
adolescents, parental opinions on why they are or are not consenting to vaccinating their children 
against HPV, and administration of vaccines in a school-based setting. Exclusion criteria 
included articles that did not pertain to adolescents. 
 The search in PubMed yielded 485 results. Fifty-four abstracts were assessed and ten 
were kept for inclusion in this review. The search in CINAHL yielded 83 results. Seventeen 
abstracts were assessed and three were kept for inclusion in this review. The rest of the articles 
used in this literature review were obtained from reviewing the bibliographies of already 
obtained studies  
 The literature review revealed a few overarching themes. Firstly, there are many reasons 
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parents (any time parents are referenced in this proposal, the author is referencing the legal 
guardian of the child) decide not to vaccinate their children against HPV, including: lack of 
education, questions about the safety of the vaccine, and that they do not think their children are 
sexually active. The review also revealed that schools are a promising venue to educate 
adolescents and their parents/legal guardians about HPV and the HPV vaccine and increase HPV 
vaccination rates. 
 Reasons why adolescents have not received the HPV vaccine. There are many reasons 
why parents are reluctant to have their adolescent children vaccinated against HPV such as fear 
of side effects, but active refusal is not always the reason, often times it is lack of education. 
Many parents are not well informed about HPV and the vaccine, especially related to vaccinating 
boys.  
 Lack of education. Many parents and adolescents were not aware of HPV and the HPV 
vaccine or do not have enough information to make an educated decision about the HPV vaccine 
(Hughes et al., 2011; Read, Joseph, Polishchuk, & Suss, 2010; Sotiriadis, Dagklis, Siamanta, 
Chatzigeorgiou, & Agorastos, 2012). Bair, Mays, Sturm, and Zimet (2008) conducted a 
qualitative study where they interviewed 40 Latina mothers from an urban pediatric clinic. The 
mothers had daughters that were between the ages of 7-14. Seventy-eight percent of the mothers 
had not heard of HPV and 68% of the sample knew nothing about cervical cancer. All mothers in 
the sample reported having had a Pap smear, but 85% of them did not know about the connection 
between HPV and Pap smears. After receiving information about the HPV vaccine, 80% of the 
mothers stated they would allow their daughters to receive the HPV vaccine. The eight mothers 
who did not agree stated they needed more information about the HPV vaccine and/or their 
daughter was too young. 
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 A qualitative study conducted in New South Wales, Australia by Bernard, Cooper 
Robbins, McCaffery, Scott, and Skinner (2011) looked at fear, the fear response, and factors 
affecting fear in adolescent girls who were going to receive the HPV vaccine. Girls from nine 
schools between the ages of 12-16 were either observed on the vaccination days at school or 
were interviewed in focus groups. Three fear responses were recorded: fear of pain, fear of 
having needle pierce skin, and fear of vaccine content and possible side effects. The results 
showed that the girls fear responses exacerbated the responses of their peers, girls were more 
stressed when waiting in large groups with peers, and the lack of privacy made fear worse. The 
results also reported that most girls knew very little about HPV and why they were receiving the 
vaccine. The misinformation that many of the girls received about the vaccine came through 
rumors from friends and family. The three-dose HPV vaccination rate ranged from 64%-90% 
among girls from those schools. 
 Cates, Ortiz, Shafer, Smith Romocki, and Coyne-Beasley (2012) performed a two phase 
qualitative study with Black parents/caregivers of 11 and 12 year old boys in North Carolina 
about designing messages to motivate parents/caregivers to vaccinate their sons against HPV. 
During the first phase of the study focus groups were conducted with parents/caregivers. 
Participants were recruited from churches and a middle school. Twenty-nine parents/caregivers 
made up the focus group sample and 76% of them were female. Results showed 
parents/caregivers were uninformed about HPV. Almost all parents were unaware that HPV can 
have serious effects on boys. Many thought HPV was only problematic for girls and they were 
surprised to hear that the HPV vaccine is recommended for boys. During the second phase of the 
study,  intercept interviews were done with 100 parents/caregivers at a pediatric and adolescent 
clinic. Seventy-seven percent of the sample was female caregivers. This study did not 
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specifically target females, but female parents/caregivers are the ones who more often chose to 
participate or were the ones bringing the child to an appointment. Results from the intercept 
interviews showed that only 11% of parents had heard of the HPV vaccine being recommended 
for boys.   
 Vaccine safety. Vaccine safety and efficacy is one of the most common reasons for HPV 
vaccine refusal cited by parents of adolescents (Gilkey, Moss, McRee, & Brewer, 2012). 
Dempsey, Abraham, Dalton, and Ruffin (2009) performed a qualitative study of 52 mothers of 
11-17 year old girls in Michigan. The mothers completed a telephone survey and answered 
questions about reasons why they accepted or declined the HPV vaccine for their daughters. 
Thirty-three mothers had accepted the HPV vaccine and 19 had declined vaccine for their 
daughters. Those who declined the vaccine had significant concerns about the safety of the HPV 
vaccine. They also generally felt their daughters were at low risk for HPV or were too young to 
receive the vaccine. 
  Fear of side effects from the vaccine is another commonly cited reason by parents who 
have not vaccinated their children against HPV (Bernard, Cooper Robbins, McCaffery, Scott, & 
Skinner, 2011; Kester, Zimet, Fortenberry, Kahn, & Shew, 2012). Sotiriadis, Dagklis, Siamanta, 
Chatzigeorgiou, and Agorastos (2012) performed a qualitative study in Greece of 5,249 women 
who had a 13-year-old son or daughter. The mothers filled out a survey to explore the factors 
affecting women’s acceptability of the vaccine for themselves, their daughters and their sons. 
The acceptability rate for vaccination of their daughters was 78.3% and 77.5% for their sons. The 
most common reasons cited by mothers about refusal of the vaccine were fear of adverse events 
and lack of knowledge about HPV and vaccination. The intention to vaccinate their children 
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decreased significantly after the vaccine became available in Greece and it coincided with a rise 
in mothers who were concerned about its potential side effects. 
 Lu, Kimar, Castellsague, and Giuliano (2011) conducted a systematic review and meta-
analysis on the safety and efficacy of HPV vaccines. The study included 13 publications 
representing seven randomized control trials. Results showed vaccines are highly efficacious in 
preventing HPV infection and associated precancerous lesions. Local and systemic side effects 
were generally mild. The most serious side effect was abnormal pregnancy related outcomes and 
this was rare.  
 A case study published by Watson, Shaw, Mochanoff, and McInnes (2009) described the 
implementation of an HPV school vaccination program in South Australia. Side effects reported 
by the adolescent girls were similar to those reported in the meta-analysis by Lu et al. (2011). 
The most common side effects reported were nausea, headache, injection site reaction, fever and 
rash. There was report of numbness in limbs, seizure, neck stiffness and a urinary tract infection 
but it is unclear whether these symptoms can be directly associated with the HPV vaccine. The 
program was offered to 50,191 female students in school classes 8-12 across 219 schools. HPV 
vaccination initiation was highest in year 8 at 83% and year 10 at 70%. Vaccination rates of 
doses two and three varied from 55% to 77% amongst the classes. The rates were impressive 
given that the vaccine initiative was announced after the school year had begun and coordination 
and implementation was completed within a six-month period. 
 Parents do not think children are sexually active. According to the CDC (2011b), the 
ideal time for adolescents to receive the HPV vaccine is between the ages of 9 to 12 so that it is 
provided before their first sexual encounter Many parents delay getting their adolescents 
vaccinated because they do not think their children are sexually active when they are (Bair et al., 
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2008; Dempsey et al., 2009; Dorrell, Yankey, & Strasser, 2009; Hughes et al., 2011). 
 A qualitative study conducted by Read, Joseph, Polishchuk, and Suss (2010) 
administered a survey to girls and their parents at an urban health clinic to assess knowledge and 
attitudes about HPV and the vaccine. The sample was made up of girls who predominantly are of 
African-American or Caribbean descent. Results revealed early sexual initiation by the girls. Out 
of the sample of 175 girls ages 13-19, 48.9% reported being sexually active at an average age of 
14.9 years. Over half of the girls who reported being sexually active have had more than one 
lifetime sexual partner. Only 55.8% of girls knew what HPV was. Seventy-two parents 
participated in the survey and 38.9% of them reported they were unsure about the HPV vaccine 
and 23.6% of parents stated they would refuse the vaccine for their daughter. The most common 
reason for refusal reported by parents was not having enough information about HPV and the 
vaccine. 
 Schools and the HPV vaccine. School-based health centers (SBHCs) and school-based 
vaccination programs are quite common in other parts of the world and HPV vaccination 
programs have been successful in these settings. SBHCs and school-based vaccination programs 
are not as common in the U.S., but they are slowly increasing in number and the majority of 
parents support them. Gustafson (2005) wrote an article about the history of SBHCs in the U.S. 
In 1990, there were only 200 SBHCs located in 45 states plus the District of Columbia, but that 
number increased to over 1500 by 2002. Sixty-one percent of SBHCs are in urban areas, 27% in 
rural areas, and 12% in suburban areas. SBHCs are mostly nurse managed with nurse 
practitioners and other healthcare providers. The mission of SBHCs is to provide access to 
primary care and preventative care for kids who are the least likely to access regular care within 
their communities.  
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 In England, a national school-based vaccination program with Cervarix® began during 
the 2008/2009 school year. Statistics show that in its first year, 80.1% of 12-13 year old girls 
received the three-dose series. In the 2009/2010 school year, 76.4% of girls ages 12-13 had 
received all three doses of the vaccine, 82.3% had received at least two doses, and 84.3% had 
received at least one dose of the HPV vaccine (Sheridan & White, 2010).  Vaccination rates in 
other countries are well above the rates among females of the same age in the U.S.  
 The literature search also highlighted studies with results that show parents are supportive 
of school-based vaccination programs. Reiter, Stubbs, Panozzo, Whitesell, and Brewer (2011) 
identified that parents, healthcare providers and school staff members are the key stakeholders in 
regards to adolescent females and HPV vaccination. An HPV education campaign was 
conducted throughout Guilford County, North Carolina. Numerous 30-40 minute informational 
sessions were held for groups made up of the key stakeholders. Data was reported from 118 
healthcare staff members, 456 school staff members, and 376 parents who attended the 
intervention sessions and 91% of them were female. Healthcare and school staff completed pre- 
and post-session surveys during the intervention. Surveys assessed objective knowledge about 
HPV and asked opinion-based questions regarding the HPV vaccine and schools. Before the 
intervention, 86% of school staff members felt middle schools were appropriate venues for HPV 
education and vaccination programs, but after the intervention, the number increased to 91%. 
Before the intervention, 79% of school staff members stated they were supportive of school-
based vaccination clinics and after the interventions, 85% stated they were supportive. Parents 
did not fill out surveys before the intervention, but after the intervention, 97% of them stated 
they would be supportive of a school-based vaccination clinic. 
 A large qualitative study conducted by Middleman and Tung (2011) assessed the 
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association between parents’ perspectives on school-located immunization programs and the 
subsequent implementation of a school-located immunization programs. A sample of 1,377 
parents who had children in middle school completed a pre-program questionnaire and 777 
parents returned a consent or refusal form for their child to be vaccinated at school. An 
unexpected finding appeared in the results of this study. Forty-two percent of parents who 
consented to having their child vaccinated at school had indicated in their pre-program survey 
that schools were not a preferred place for children to receive vaccines. The authors suggested 
that rates of parents who actually consent for their child to receive vaccines at school might be 
higher than expected from responses on assessing parental attitudes about school-based 
vaccination. This study was not about HPV vaccine, only tetanus, diphtheria, acellular pertussis 
(Tdap) and meningococcal vaccines were being offered to the adolescents. 
 A qualitative cross-sectional study conducted by Kelminson et al. (2012) mailed surveys 
home to 805 parents of incoming sixth grade students in three public middle schools in Aurora, 
Colorado. The purpose of the survey was to assess parental attitudes about administering 
vaccines at school. Five hundred surveys were returned and 85% of those who completed the 
survey were female. This study did not target mothers, but they were the ones choosing to fill out 
the surveys about their child’s health. Seventy-one percent of parents stated they would consent 
to their children receiving vaccines at school. More parents stated they would consent for their 
children to receive the Tdap or meningococcal vaccine than the HPV vaccine, but 72% of parents 
responded that they would consent for their children to receive the HPV vaccine at school.  
 Reiter, McRee, Pepper, and Brewer  (2012) conducted a qualitative study that sent an 
online survey to parents in the U.S. with adolescent sons aged 11-17. The study assessed 
attitudes and beliefs about HPV vaccination and boys. Four hundred and four parents completed 
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the survey and 54% were female and 46% were male. This is the only study from the literature 
search that had a sample of nearly equal participation of both mothers and fathers The authors 
did not report any reason as to how or why so many fathers completed the survey. Parents were 
presented with mock situations that offered to vaccinate their children at a school clinic. As other 
studies have shown, parents agreed to the HPV vaccination more often when the HPV vaccine 
was offered with other routine vaccinations required for adolescents. Parents also agreed to the 
HPV vaccination more often when presented with a consent form for them to “opt-in” rather than 
“opt-out” of the vaccination for their children. 
 Kadis et al. (2011) performed a study about whether mothers would support an HPV 
vaccination program in their child’s school. The nationally representative sample consisted of 
496 mothers of 11-14 year-old females who completed an online survey. Out of the sample, 20% 
of mothers reported that their daughters had already completed the series of HPV vaccination, 
31% of mothers reported that their daughters had received at least one dose of the vaccine, and 
48% stated they intended to have their daughter vaccinated within the next year. Sixty-seven 
percent of the mothers who had already had their daughters receive one or all of the HPV 
vaccines or intended to vaccinate their daughters against HPV stated they would agree to their 
daughters receiving the HPV vaccine at school.  
Synthesis of the Evidence 
 The majority of the studies had a qualitative design, which is considered a lower level of 
evidence according to the Johns Hopkins Nursing Evidence-Based Practice Rating Scale 
(Newhouse, Dearholt, Poe, Pugh, & White, 2007), but qualitative studies are appropriate for 
answering the question: how can nurses increase awareness about HPV and the HPV vaccine and 
increase vaccination rates in adolescents? One limitation of many of the articles was the use of 
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convenience samples. Another limitation of many of the articles was that the results were not 
generalizable to the U.S. populations because either the study was performed in another country 
or only in a small area of the U.S. Despite these limitations, the literature review provides many 
avenues that nurses can follow to increase awareness about HPV and the HPV vaccine and 
increase vaccination rates in adolescents 
 Nursing interventions need to primarily focus on increasing general educational messages 
about HPV and the vaccine for both parents and adolescents. The literature clearly reveals that 
lack of education is one of the biggest, if not the biggest reason why HPV vaccination rates are 
so low. Outreach to parents of adolescents, particularly parents of boys, is imperative to educate 
them that their adolescents should receive the HPV vaccine, as many parents are still unaware 
that the HPV vaccine is recommended for boys as well as girls. Educational messages should 
also include information that the HPV vaccine is safe, but inform parents and adolescents about 
the most common side effects associated with the vaccine.  
 Schools that have SBHCs and/or school-based vaccination programs are promising 
avenues to increase knowledge about HPV and the HPV vaccine and increase HPV vaccination 
rates. HPV vaccination programs at SBHCs in other parts of the world have been highly 
successfully and have had vaccination rates of up to 90% (Bernard et al, 2011). As the literature 
review revealed, a large number of parents stated they would consent to their child receiving 
vaccinations at school and the results from one study showed that when the vaccination program 
was actually implemented, more parents consented to their child receiving vaccines than was 
anticipated from results of pre-program survey. Nurses can educate parents and adolescents 
about HPV and the HPV vaccine at schools that have SBHCs and remind them that the 
adolescent can receive the HPV vaccine at school. Having adolescents vaccinated at school also 
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provides an opportunity to decrease the rates of missed opportunities. Healthcare providers 
working at the SBHCs can ensure that adolescents already coming in for routine physicals and/or 
other recommended vaccines also get the HPV vaccine.  
 The literature review identified barriers to vaccinating adolescents against HPV. One 
barrier is the fear response adolescent girls have toward vaccinations/injections. They have fears 
of pain and having the needle pierce their skin. Concern about safety of the HPV vaccine and its 
possible side effects are also major barriers. Both parents and adolescents have identified with 
this concern. Another barrier are parents who think the HPV vaccine is not yet necessary for 
their children because they do not think their children are sexually active, when in fact they are..  
Theoretical Framework 
 It is essential to have a theoretical framework on which to focus implementation of 
research-based interventions in practice (White & Dudley-Brown, 2012). One such theory is the 
Health Belief Model (HBM). This model (Appendix A) is composed of six constructs that 
“…influence people’s decisions about whether to take action to prevent, screen for and control 
illness” (NCI, 2005, p. 13). The HBM can be applied to an evidence-based intervention to 
increase knowledge in parents and adolescents about HPV and the HPV vaccine and increase 
HPV vaccination rates in adolescents. 
 The authors of the HBM state people will be ready to act on a health decision if all six of 
the constructs are present. The first construct is perceived susceptibility. People must believe 
they are susceptible to the condition. The second construct is perceived severity. People must 
believe the condition has serious consequences. The third construct is perceived benefits. People 
must believe taking action would reduce their susceptibility or its severity. The fourth construct 
is perceived barriers. People must believe the costs of taking the action are outweighed by the 
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benefits. The fifth construct is cue to action. People must be exposed to factors that prompt 
action. The sixth and final construct is self-efficacy. People must feel confident in their ability to 
successfully perform the action. The authors comment that health motivation is central to the 
HBM and the model is useful for designing short and long-term behavior change strategies (NCI, 
2005).  
 The HBM can be applied to a scenario where a mother and her son decide whether to 
vaccinate the son against HPV. The adolescent son receives education about HPV and the HPV 
vaccine in his health class at school and his mother hears similar information at a meeting she 
attended in the community (perceived susceptibility). Both mother and son learn that HPV can 
cause genital warts and cancer in males and females (perceived severity). They both learn that 
the HPV vaccine is recommended for adolescents, ages 9-26, and can prevent the son from 
getting the most common types of HPV that cause genital warts and cancer (perceived benefits). 
The mother and son learn that the HPV vaccine is safe and are aware of the most common side 
effects caused by the vaccine. They learn that the HPV vaccine is covered by most insurance 
companies and is available at the SBHC at the son’s school and/or at his primary care provider’s 
office (perceived barriers). After hearing this information, the mother and son are both provided 
information to take home with the contact information of the SBHC and how to make an 
appointment for the son to receive the vaccine. The mother and son decide that the son should 
receive the HPV vaccination and call to make an appointment (cue to action and self-efficacy). 
Project Description, Implementation, and Monitoring 
Population/Community 
 The city of Holyoke is in the western part of the Commonwealth of Massachusetts. It is 
located in Hampden County. The population of Holyoke in 2010 was 39,880 people. Out of the 
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39,880 people living in Holyoke 19,313 (48.4%) people identified themselves as Hispanic or 
Latino and 20,567 (51.6%) identified themselves as not Hispanic or Latino. Of those who did not 
identify as Hispanic or Latino, 18,651 (46.8%) identified as white alone, 961 (2.4%) as Black or 
African American alone, 402 (1%) as Asian alone, 7 (0%) as Native Hawaiian or Pacific Islander 
alone, 43 (0.1%) as American Indian or Alaska Native alone, 61 (0.2%) as some other race alone, 
and 442 (1.1%) identified as two or more races. (U.S. Census Bureau, 2010). 
 Holyoke has two public high schools, Holyoke High School and William J. Dean 
Vocational Technical High (Dean Tech) with students in grades 9-12. During the 2012/2013 
school year, 1,354 students were enrolled at Holyoke High School (Massachusetts (Mass.) 
Department (Dept.) of Elementary and Secondary Education (ESE), 2013a) and 517 at Dean 
Tech (Mass Dept. of ESE, 2013c). Out of the 1,354 students at Holyoke High School, 3.3% 
identified as African American, 0.9% Asian, 68.9% Hispanic, 0% Native American, 26.4% white, 
0% Native Hawaiian or Pacific Islander, and 0.5% identified as multi-race, non-Hispanic (Mass 
Dept. of ESE, 2013a). Out of the 517 students at Dean Tech, 1.5% identified as African 
American, 0.2% Asian, 91.3% Hispanic, 0% Native American, 6.8% white, 0.2% Native 
Hawaiian or Pacific Islander, and 0% identified as multi-race, non-Hispanic (Mass Dept. of ESE, 
2013c). Among the student body at Holyoke High School, 46.3% of students’ first language is 
not English and 10.9% of students are limited English language proficient (Mass Dept. of ESE, 
2013b). Among the student body at Dean Tech, 69.1% of students’ first language is not English 
and 30.8% of students are limited English language proficient (Mass Dept. of ESE, 2013d). 
  At Holyoke High School, 74.9% of students are considered low income, 68.1% of 
students qualify for free lunch, and 6.8% of students qualify for reduced lunch (Mass Dept. of 
ESE, 2013b). At Dean Tech, 95.6% of students are considered low income, 91.5% of students 
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qualify for free lunch, and 4.1% of students qualify for reduced lunch (Mass Dept. of ESE, 
2013d). To qualify for free or reduced lunch in the state of Mass., the parent(s)/caregiver(s) must 
have an annual household income before taxes that does not exceed $26,955 if two people live in 
the household; $33,874 if three people live in the household; $40,793 if four people live in the 
household; $47,712 if five people live in the household; $54,631 if six people live in the 
household; $61,550 if seven people live in the household; and $68,469 if eight people live in the 
household. For larger households, add $6,919 for each additional person in the home 
(Benefits.gov, 2012). In 2009/2010, the national average of high school students who were 
eligible to receive free or reduced lunch rates was 38% (Institute of Educational Sciences, 2010). 
 In 2012, out of 340 students who entered ninth grade at Holyoke High School in 2008, 
the 4-year graduation rate was 67.9%. Among the other students who did not graduate in four 
years, 7.9% were still attending school, 16.2% had dropped out, 3.2% had completed their 
education but had not graduated, and 3.8% had earned a GED (Mass Dept. of ESE, 2012a). In 
2012, out of 167 students who entered 9th grade at Dean Tech in 2008, the 4-year graduation rate 
was 27.5%. Among the other students who did not graduate in four years, 15.6% were still 
attending school, 30.5% had dropped out, 10.8% had completed their education but had not 
graduated, and 3.0% had earned a GED (Mass Dept. of ESE, 2012b).  The national average 4-
year graduation rate in public schools is 75.5% and the average in the state of Mass. is over 80% 
(Institute of Educational Sciences, 2012). Students attending Holyoke High School and Dean 
Tech are a racially and ethically diverse group of adolescents who come from a low 
socioeconomic and education status. 
 ACIP recommends that HPV vaccination begin in adolescents starting at ages 11 to 12 so 
that children receive the vaccine before they begin having sexual contact, yet they point out that 
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both males and females ages 13 to 26, also benefit from the vaccine. Males and females between 
the ages of 13 to 26 who have not had sexual contact will benefit from the vaccine and those who 
already are sexually active may not have been exposed to all the oncogenic strains of HPV and 
the vaccine will provide benefit to them as well (CDC, 2007; CDC, 2011c). Even though 
students attending Holyoke High School and Dean Tech are older than age 12, the HPV vaccine 
is beneficial to them if they have not already received the three dose series.  
Needs Assessment/Organizational Analysis 
 Mary Fago, Adult Nurse Practitioner (ANP), clinical director of Holyoke’s SBHCs was 
interviewed by the Doctorate of Nursing Practice (DNP) student researching capstone project 
ideas related to HPV vaccination rates and SBHCs. Holyoke Public Schools have three SBHCs 
and two of them are located at Holyoke High School and Dean Tech. It became apparent that 
there was a need to educate adolescents and their parents about HPV and the HPV vaccine. The 
sites have offered the HPV vaccine, but have not had time to do education with students and their 
parents about the vaccine, so very few doses have been administered. At these SBHC sites there 
are likely many missed opportunities for adolescents to receive the HPV vaccine (M. Fago, 
personal communication, February 14, 2013). 
 The Director also revealed that she felt there is a lack of awareness about HPV and the 
HPV vaccine amongst adolescents and their parents. A new sex education program was 
implemented at the high schools three years ago, but no specific content was included about 
HPV and its consequences and the HPV vaccine. The Director stated she would like to do more 
education about HPV and the HPV vaccine, but has lacked the time to do so. 
 An assessment and analysis of the situation at Holyoke High School and Dean Tech was 
performed with the Director and it was determined that an HPV education project was needed for 
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both adolescents and parents. As mentioned previously, Black and Hispanic women have higher 
rates of cervical cancer and women who lived in households with incomes at less than 200 
percent of the poverty level or had not graduated from high school, were less like to have had a 
Pap test. Black women have higher rates of vaginal and oropharyngeal cancer and Black men 
have higher rates of oropharyngeal and anal cancer. Hispanic men have higher rates of penile 
cancer. A large proportion of the students attending Holyoke High School and Dean Tech are 
Hispanic and the majority of them live below the poverty level, which puts them at a higher risk 
for HPV-associated cancers. Also mentioned previously were the low rates of HPV vaccine 
series completion and that SBHCs are an opportune location to receive all three doses. Students 
do not have to miss school as the vaccine is provided on site and parents need to have only 
signed a consent form, but do not need to be present when the vaccines are given.  
Stakeholder Support 
 The Director, the school nurse leader, and the head of health education for Holyoke 
Public Schools approved this capstone project. Mary Fago signed the letter of agreement 
(Appendix B). 
Resources, Barriers, and Facilitators 
 The resources needed to implement this research translation project were space, supplies, 
and time. Space was needed to teach students and parents about HPV and the HPV vaccine. 
Supplies were needed to create educational materials that are appropriate for both adolescents 
and their parents. The HPV vaccine is available in the school-based clinic. Time was needed to 
create the educational materials, to teach the students do outreach to parents, and to gather and 
analyze the results of the project. The DNP student managed her time to complete the listed tasks 
during the spring 2013 semester.  
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 Teachers, parents and adolescents could have been potential barriers to the success of this 
project. If teachers were not supportive of the HPV vaccine, they could have persuaded 
adolescents to not get the vaccine or not create a supportive learning environment for students to 
be educated about HPV and the HPV vaccine. Parents who were not supportive of the HPV 
vaccine could have convinced their children that the vaccine is harmful or not necessary and they 
have the ultimate say as to whether their child receives the vaccine. Adolescents who were 
fearful or misinformed about the vaccine could also have persuaded their parents to not let them 
receive the vaccine.  
 The primary facilitators of the capstone project were the DNP student and the student’s 
capstone project committee. The DNP student was responsible for completing the work and the 
committee was there to advise, mentor, and guide the student through all phases of the project. 
Other facilitators of the capstone project were Mary Fago, clinical director of Holyoke’s SBHCs 
and the health teachers at Holyoke High School and Dean Tech. 
Protocol/Plan 
 Goals and objectives. There were two primary objectives of this capstone project. The 
first goal was to increase knowledge about HPV and the HPV vaccine in students and parents of 
students who attend Holyoke High School and Dean Tech. The second goal was to increase the 
number of parents of adolescents who intended to vaccinate their adolescents against HPV and 
also increase the number of adolescents who intended to receive the HPV vaccine. 
 Project design and evaluation. The research translation method that was used for this 
project was an educational intervention and the Plan-Do-Study-Act (PDSA) model. PDSA 
projects are used when “…data are collected to demonstrate that change by interventions resulted 
in improvement” (Speroff & O’Connor, 2004, p. 21). A PDSA project was used to develop an 
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intervention to educate parents and adolescents about HPV and the HPV vaccine, which will 
then lead to higher intent to vaccinate adolescents against HPV. 
 For this project, evidence-based research had already been collected. The rationale for 
this project was centered on evidence-based research that shows when the HPV vaccine is 
offered in a school-based setting, vaccine rates are higher (Brabin et al., 2008; Reiter et al., 2012) 
and that parents and adolescents need more education about HPV and the HPV vaccine. Based 
on this research, a proposed protocol was developed to educate parents and adolescents about 
HPV and the HPV vaccine and then they would be reminded of the opportunity to vaccinate their 
adolescents through the SBHC (Plan).  
  The DNP student attended ninth grade health classes at both Holyoke High School and 
Dean Tech to teach content to students about HPV and why they should receive the HPV vaccine. 
The DNP student did one 50-minute class period with each section of ninth grade health class at 
both schools. The presentation emphasized that the vaccine is now available for boys as well as 
girls and that it is important for both sexes to receive the vaccine. The information presented to 
the students was taken from the CDC website and also from an HPV curriculum developed by 
Planned Parenthood for parents and adolescents (Bernstein et al., 2008) and formulated into an 
interactive presentation and educational handout (Appendix C).  A demographic instrument and 
pre-test (Appendix D) was prepared and administered at the beginning of class. Post-tests 
(Appendix E) were also prepared and administered at the end of class after the educational 
intervention (Do). 
 The DNP student had proposed to give a presentation to parents about HPV and the HPV 
vaccine and provide parents with an opportunity to ask questions and discuss their concerns 
about the vaccine at the high schools or the Holyoke Boys and Girls Club parent night. A 
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demographic instrument  pre-test   (Appendix F) and post-test (Appendix G) were prepared for a 
parent presentation, but the presentation was cancelled and unable to be rescheduled. The high 
schools did not have a forum for this type of presentation and the Boys and Girls Club was not 
able to reschedule the presentation during the project timeframe (Do). 
  The questions for the pre-tests and post-tests for both the adolescents and the parents 
were based on a study (permission was obtained by the DNP student) by Kennedy, Sapsis, 
Stokley, Curtis, and Gust (2011), the Planned Parenthood HPV curriculum (Bernstein et al., 
2008), and the HBM. The standardized pre-test and post-test were comprised of the exact same 
ten multiple-choice questions. The questions were used to measure knowledge levels about HPV 
and the HPV vaccine, their perceived severity to HPV, the perceived benefits of the HPV 
vaccine, the perceived barriers of the HPV vaccine, their cues to action about receiving the HPV 
vaccine, and their intent to receive the HPV vaccine (Do).  
 The DNP student did outreach to parents to inform them about HPV and the HPV 
vaccine. The student staffed a Teen Clinic table at a parent information night at Holyoke High 
School for parents of incoming ninth graders. The table had information about the HPV vaccine, 
the Teen Clinic, and the DNP student spoke with parents about the HPV vaccine and that the 
vaccine was available through the Teen Clinic. The student also staffed a table on behalf of the 
Teen Clinic at a 5K run in Holyoke and had information about HPV and the HPV vaccine for 
parents and adolescents. The student had a sign that stated, “Come talk about HPV and get a 
popsicle for free” to give people an incentive to visit the table. The student spoke with parents 
and adolescents and gave them information and answered their questions about HPV and the 
HPV vaccine (Do).  
INCREASING HPV VACCINATION RATES 28 
 The DNP student prepared an informational handout that was sent home with all ninth 
grade students at Holyoke High School and Dean Tech. The handout was an information sheet 
written by the CDC (Appendix H) with a small attachment stapled to it (Appendix I) that 
reminded parents and students that the SBHC had the HPV vaccine available and was an 
opportune site for students to receive the HPV vaccine. The attachment provided information on 
how adolescents could schedule an appointment at the SBHC. The handout was double-sided in 
both English and Spanish. Informational brochures and posters that are specifically aimed at 
adolescents were also ordered and obtained about HPV and the HPV vaccine and were placed in 
the SBHC (Do).  
  To evaluate the project outcomes, three instruments were used: the demographic 
instrument (no identifying information was collected from students), the pre-test, and post-test. 
All data collected during the protocol was analyzed to see if the goals of the project were 
accomplished. (Study).  
 The first goal of increasing knowledge about HPV and the HPV vaccine in students and 
their parents was only evaluted in the students by administering the pre-test and post-test before 
and after the eductional intervention. Improvement in the test scores demonstrated an increase in 
knowledge in the students. The second goal of increasing the number of parents of adolescents 
who intended to vaccinate their adolescents against HPV and also increasing the number of 
adolescents who intended to receive the HPV vaccine, was only evaluated in the adolescents. 
This was measured on the adolescents’ pre-tests and post-tests. Students were asked on the pre-
test if they have received the HPV vaccine and if not, whether they intended to receive the HPV 
vaccine. On the post-test, students were again asked if they intended to receive the HPV vaccine. 
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An increase in adolescents who intended to receive the HPV vaccine demonstrated that the 
project was successful.  
 Then all the data was reviewed and analyzed. It was determined the protocol was 
successful and knowledge about HPV and the HPV vaccine increased and intent to vaccinate 
rates increased. It was also determined that the fliers and consent forms could be sent home to 
students in other grades at Holyoke High School and Dean Teach or at other schools that have 
SBHCs to increase HPV awareness and vaccination rates at those sites as well (Act).  
 Costs and resources. The expenses for this project were staff time and supplies. Staff 
time was needed to allow the DNP student to present in the ninth grade health classes. Time was 
needed to create/gather the educational materials, to teach the students, to do outreach to the 
parents, and to gather and analyze the results of the project. The location for the educational 
programs for the adolescents was at school and there was no fee involved. The supplies for the 
educational program and the parent outreach were approximately $300. The DNP student 
covered this cost. Brochures and posters were ordered at no cost from the CDC, which the DNP 
student used and reproduced on a copy machine. 
 IRB approval and ethical considerations. This capstone project did not require IRB 
approval because this was a student program improvement project. The project involved human 
subjects, but did not involve any research activities. No identifying information was collected on 
the adolescents or their parents.  
 Implementation and timeline.  The capstone project proposal was approved by the DNP 
student’s capstone committee in March 2013, before the project began. Once the committee 
approved the proposal, the DNP student immediately created and ordered the educational 
materials needed for the educational sessions, the pre and post-tests for the students and parents 
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were written, and supplies for the parent outreach were gathered. The informational handout for 
parents was also prepared and copied. The educational interventions and parent outreach was 
performed during May and June 2013. The data was analyzed and the final write-up of the 
capstone project was completed in May and June 2013. The timeline below was the proposed 
workplan for the capstone project in 2013. 
Table 1. Timeline 
Task March April May June 
Capstone  
Project  
Proposal 
X     
Develop 
Parent 
Information 
Form 
X X     
Develop 
Student/Parent 
Educational 
Information 
X  X     
Educational 
Sessions with 
Students and  
Parents 
 X X    
Data 
Collection and 
Analysis 
 X X    
Interpretation 
of Results 
 X X X 
Complete 
Capstone  
Write-up 
  X X 
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Evaluation 
Demographic Data 
 The adolescent sample was a convenience sample of all ninth graders who had health 
class during the spring semester at Holyoke High School and Dean Tech. This comprised about 
half of the entire ninth grade class at each school. The sample was 52% female and 48% male. 
Twenty-one percent of the students were 14 years old, 62% were 15 years old, 16% were 16 
years old, and 1% was 17 years old. Out of the sample, 63% of students identified as Hispanic, 
18% as white, 12% as Hispanic, more than one race, 5% as non-Hispanic, more than one race, 
and 2% as Black or African American.  
Data Analysis-Pre-tests/Post-tests 
 The DNP student entered all data from the adolescents’ pre-tests and post-tests into an 
Excel spreadsheet. Only adolescents who completed the demographic data, pre-test, and post-test 
results were used in this analysis (N=164). More students (N=169) were present for the 
educational intervention, but they had missing data. The mean scores from each question were 
calculated and scores from the pre-tests were compared with the post-tests scores. Scores were 
compared for the group as a whole and also scores of males versus females. No data was able to 
be collected from the parents because the presentation for the parents was not performed and the 
two outreach sessions for parents were not amenable to collecting data.  
 Table 2 shows all the students’ mean scores on each pre-test and post-test question. Table 
3 shows the students’ mean scores on each pre-test and post-test question, but compares the 
scores by sex.  
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Table 2. Entire Group Scores 
Question  Pre-Test Score Post-Test Score 
1-If I am infected with HPV, I could  
get genital warts and/or cancer. 
Agree-26% 
Disagree-14% 
Unsure-60% 
Agree-95% 
Disagree-2% 
Unsure-3% 
2-HPV is one of the most common 
sexually transmitted infections in the 
United States. 
True-72% 
False-28% 
True-98% 
False-2% 
3-The highest rates of new genital 
HPV infections occur in young 
adults between the ages of 15-24. 
87%-True 
13%-False 
True-94% 
False-6% 
4-How is HPV transmitted? Select 
all the correct answers. 
A. Skin-to-skin contact 
B. Contact with infected blood 
C. An infected person coughs or 
sneezes on another person 
D. Vaginal, oral, or anal sex 
7% Chose A & D 
95% Chose A or D 
62% Chose A & D 
100% Chose A or D 
5-Who should receive the HPV 
vaccine? 
1% Girls only 
0% Boys only 
99% Girls and Boys 
1% Girls only 
0% Boys only 
99% Girls and Boys 
6-Have you received the HPV 
vaccine? 
*If you answered yes to question 6, 
do not answer any more questions 
Yes-19% 
No-27% 
Unsure-54% 
Yes-33% 
No-27% 
Unsure-40% 
7-I believe I could be at risk (now or 
in the future) for getting HPV. 
Agree-15% 
Disagree-36% 
Unsure-49% 
Agree-43% 
Disagree-23% 
Unsure-34% 
8-There is a vaccine I could receive 
to prevent myself from getting the 
most serious types of HPV. 
Agree-65% Agree-87% 
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Disagree-3% 
Unsure-32% 
Disagree-1% 
Unsure 12% 
9-There is someone I could talk to 
(parent, nurse, doctor, friend, 
teacher) about my questions and 
concerns about HPV and the HPV 
vaccine. 
Agree-81% 
Disagree-3% 
Unsure-16% 
Agree-92% 
Disagree-2% 
Unsure-6% 
10-If you have not received the HPV 
vaccine, do you intend to get the 
HPV vaccine in the future? 
Yes-63% 
No-4% 
Unsure-33% 
Yes-76% 
No-4% 
Unsure-20% 
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Table 3. Males Versus Female Scores 
Question Pre-Test Score Post-Test Score 
1-If I am infected with HPV, I 
could get genital warts and/or 
cancer. 
Males Females Males Females 
Agree-28% Agree-25% Agree-94% Agree-97% 
Disagree-16% Disagree-10% Disagree-3% Disagree-1% 
Unsure-56% Unsure-65% Unsure-3% Unsure-2% 
2-HPV is one of the most 
common sexually transmitted 
infections in the United States. 
Males Females Males Females 
True-66% True-77% True-97% True-98% 
False-34% False-23% False-3% False-2% 
3-The highest rates of new 
genital HPV infections occur 
in young adults between the 
ages of 15-24. 
Males Females Males Females 
True-86% True-87% True-92% True-95% 
False-14% False-13% False-8% False-5% 
4-How is HPV transmitted? 
Select all the correct answers. 
A. Skin-to-skin contact 
B. Contact with infected 
blood 
C. An infected person 
coughs or sneezes on 
another person 
D. Vaginal, oral, or anal 
sex 
Males Females Males Females 
8% chose A 
and D 
5% chose A 
and D 
53% chose A 
and D 
73% chose A 
and D 
91% chose A 
or D 
99% chose A 
or D 
100% chose 
A or D 
100% chose 
A or D 
5-Who should receive the 
HPV vaccine? 
Males Females Males Females 
Girls only-2% Girls only-0% Girls only-1% Girls only-0% 
Boys only-0% Boys only-0% Boys only-0% Boys only-0% 
Girls and 
Boys-98% 
Girls and 
Boys-100% 
Girls and 
Boys-99% 
Girls and 
Boys-100% 
6-Have you received the HPV 
vaccine? 
Males Females Males Females 
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*If you answered yes to 
question 6, do not answer any 
more questions 
Yes-18% Yes-13% Yes-33% Yes-33% 
No-35% No-37% No-27% No-27% 
Unsure-47% Unsure-50% Unsure-40% Unsure-40% 
7-I believe I could be at risk 
(now or in the future) for 
getting HPV. 
Males Females Males Females 
Agree-18% Agree-13% Agree-45% Agree-41% 
Disagree-35% Disagree-37% Disagree-22% Disagree-35% 
Unsure-47% Unsure-50% Unsure-33% Unsure-24% 
8-There is a vaccine I could 
receive to prevent myself from 
getting the most serious types 
of HPV. 
Males Females Males Females 
Agree-60% Agree-69% Agree-83% Agree-91% 
Disagree-5% Disagree-1% Disagree-0% Disagree-2% 
Unsure-35% Unsure-30% Unsure-17% Unsure-7% 
9-There is someone I could 
talk to (parent, nurse, doctor, 
friend, teacher) about my 
questions and concerns about 
HPV and the HPV vaccine. 
Males Females Males Females 
Agree-81% Agree-82% Agree-91% Agree-93% 
Disagree-5% Disagree-1% Disagree-2% Disagree-2% 
Unsure-14% Unsure-17% Unsure-7% Unsure-5% 
10-If you have not received 
the HPV vaccine, do you 
intend to get the HPV vaccine 
in the future? 
Males Females Males Females 
Yes-63% Yes-63% Yes-74% Yes-78% 
No-5% No-3% No-6% No-2% 
Unsure-32% Unsure-34% Unsure-20% Unsure-20% 
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Interpretation of the Findings 
 The data was analyzed by looking at the findings that were relative to the pre-test and 
post-test question clusters that align with each construct of the HBM. The questions that had to 
do with knowledge about HPV and the HPV vaccine all had an increase in scores. In the pre-test, 
72% of students answered the question that HPV is one of the most common sexually 
transmitted diseases in the U.S. correctly and in the post-test, 98% of students answered it 
correctly. In the pre-test, 66% of males answered the question correctly and in the post-test, 97% 
of males answered it correctly, versus 77% of females in the pre-test and 98% of females in the 
post-test. In the pre-test, 87% of student answered the question that the highest rates of new 
genital HPV infections occur in young adults between the ages of 15-24 correctly and in the 
post-test, 94% answered it correctly. In the pre-test, 86% of males answered the question 
correctly and in the post-test, 92% of males answered it correctly, versus 87% of females in the 
pre-test and 95% of females in the post-test. In the pre-test, 7% of students identified both ways 
HPV is transmitted, by skin-to-skin contact and through vaginal, oral, or anal sex correctly and in 
the post-test, 62% identified both answers correctly. In the pre-test, 8% of males and 5% of 
females identified both answers correctly and in the post-test, 53% of males and 73% of females 
identified both answers correctly. In the pre-test, 95% of students identified one of the two ways 
HPV is transmitted correctly and that increased to 100% in the post-test. In the pre-test, 91% of 
males and 99% of females could identify one of the two ways, which also increased to 100% in 
both groups in the post-test. In both the pre-test and post-test, 99% of students knew that both 
girls and boys should receive the HPV vaccine. In the pre-test and post-test, 100% of females 
answered this question. In the pre-test, 2% of males thought the HPV vaccine was for girls only 
and that decreased to 1% of males in the post-test.  
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 In the pre-test question about the perceived severity of HPV, 26% of students agreed that 
if they were infected with HPV, they could be at risk for genital warts and/or cancer. In the post-
test, 95% of students agreed they could be at risk. In the pre-test, 28% of males perceived the 
severity of HPV and 25% of females. In the post-test, 94% perceived the severity of HPV and 
97% of females.  
 The pre-test asked if students had been vaccinated against HPV or if they were unsure. 
Nineteen percent stated, yes they had received the vaccine, 27% stated they had not received the 
vaccine, and 54% were unsure. This number should have remained the same in the post-test 
because no one received the vaccine while in health class, but the numbers changed. In the post-
test, 33% of students reported they had received the HPV vaccine, 27% stated they had not, and 
40% stated they were unsure. These response rates were the same for males and females. In the 
pre-test, 18% of males stated they had received the HPV vaccine, 35%, stated they had not, and 
47% were unsure. These numbers changed in the post-test to 33% of males stating they had 
received the HPV vaccine, 27% stating they had not, and 40% were unsure. In the pre-test, 13% 
of females stated they had received the HPV vaccine, 37%, stated they had not, and 50% were 
unsure. These numbers changed in the post-test to 33% of females stating they had received the 
HPV vaccine, 27% stating they had not, and 40% were unsure.  
 The students who stated they had not received the HPV vaccine or were unsure if they 
had received it were sorted by sex and race/ethnicity. Among the 53 males, 59% were Hispanic, 
19% were white, 15% were Hispanic, more than one race, 6% were non-Hispanic, more than one 
race, and 1% were Black or African American. In the 56 females who reported they had not 
received the HPV vaccine or were unsure, 70% were Hispanic, 14% were white, 8% were 
Hispanic, more than once race, 4% were non-Hispanic, more than once race, and 4% were Black 
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or African American. Also out of the 109 students who stated they had not received the HPV 
vaccine or were unsure, 21% of them were 14 years old, 62% were 15 years old, 16% were 16 
years old, and 1% was 17 years old. 
 If the students stated they had received the HPV vaccine, they did not answer any more 
questions. If students stated they had not or were unsure if they had received they HPV vaccine, 
they completed four more questions. A question about whether students felt they were at risk 
now or in the future for getting HPV had responses on the pre-test that showed 15% agreed with 
this statement, 36% disagreed, and 49% were unsure. In the post-test, 43% of students agreed 
they could be at risk now or in the future for HPV, 23% disagreed and, 34% were still unsure. In 
the pre-test, 18% of males and 13% of females felt they could be at risk for HPV, 35% of males 
and 37% of females felt they were not at risk for HPV, and 47% of males and 50% of females 
were unsure. In the post-test, 45% of males and 41% of females felt they could be at risk for 
HPV, 22% of males and 35% of females felt they were not, and 33% of males and 24% of 
females remained unsure if they were at risk now or in the future of getting HPV. 
 The next question asked if students thought there was a vaccine that could prevent them 
from getting the most serious types of HPV, which demonstrated the perceived benefits of the 
HPV vaccine. In the pre-test, 65% of students agreed with this statement, 3% disagreed, and 32% 
were unsure. In the post-test, 87% of students agreed with this statement, 1% disagreed, and 12% 
remained unsure. In the pre-test, 60% of males and 69% of females agreed there was a vaccine 
that could prevent them from getting HPV, 5% of males and 1% of females disagreed, and 35% 
of males and 30% of females were unsure. In the post-test, 83% of males and 91% of females 
agreed, 0% of males and 2% of females disagreed, and 17% of males and 7% of females 
remained unsure. 
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 In the pre-test, 81% of students agreed, 3% disagreed, and 16% were unsure if there was 
someone they could talk to about their questions and concerns about HPV and the HPV vaccine. 
This assessed whether students felt there were perceived barriers to getting the HPV vaccine. In 
the post-test, 92% of students agreed there was someone they could talk to, 2% disagreed, and 
6% remained unsure. In the pre-test, 81% of males and 82% of females agreed there was 
someone they could talk to, 5% of males and 1% of females disagreed, and 14% of males and 
17% of females were unsure. In the post-test, 91% of males and 93% of females agreed there 
was someone they could talk to about HPV. Two percent of males and 2% of females disagreed 
with this and 7% of males and 5% of females remained unsure if there was someone they could 
talk to about HPV. 
 The last question asked the students who had answered that they had not received the 
HPV vaccine, whether they intended to get the HPV vaccine in the future. This assessed the 
students’ cues to actions. In the pre-test, 63% of students stated they intended to receive the HPV 
vaccine, 4% stated they did not intend to received the HPV vaccine, and 33% were unsure. In the 
post-test, 76% of students stated they intended to receive the HPV vaccine, 4% stated they did 
not intend to receive it, and 20% remained unsure. In the pre-test, 63% of both males and 
females stated they intended to receive the HPV vaccine, 5% of males and 3 of females stated 
they did not intend to receive the HPV vaccine, and 32% of males and 34% of females were 
unsure. In the post-test, 74% of males and 78% of females stated they intended to receive the 
HPV vaccine, 6% of males and 2% of females stated they did not intend to receive the HPV 
vaccine, and 20% of both males and females remained unsure about whether they intended to 
receive the HPV vaccine.  
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 There was also feedback that was not purposefully gathered during this capstone project, 
but is important to be presented here. The DNP student reported that the ninth grade students 
were very engaged during the class periods. Students asked a plethora of questions about HPV 
and the HPV vaccine. One student stated “Thank you for taking the time to inform us about this.” 
Another student stated, “Why hasn’t anyone else told us about HPV, this is important!” A group 
of three girls after the presentation stated they were all going to the Teen Clinic after school to 
pick up permission slips to take home for their parents to sign. At least five students stated they 
were taking the HPV handout they received in class home to their parents to talk about with them. 
When discussing possible side effects of the HPV vaccine, three students in different periods all 
raised their hands and commented that they had recently received the vaccine. Two reported 
having no side effects and one stated, “It hurt a little, but I am fine.”  One parent at an outreach 
session stated, “My son can receive this vaccine? I didn’t know that. I will make him an 
appointment right away.”  
Discussion 
 The first goal of increasing knowledge about HPV and the HPV vaccine in students and 
their parents was partially met. Results from the educational intervention with the students 
showed an increase in knowledge about HPV and the HPV vaccine. There was a 26% overall 
increase in scores on the question about HPV being one of the most common sexually 
transmitted diseases in the U.S. There was a 7% overall increase in scores on the question about 
the highest rates of new genital HPV infections occuring in young adults ages 15-24. There was 
also a 55% overall increase in the scores on the question about identifying both ways HPV is 
transmitted. There may have been an increase in knowledge amongst parents to whom the DNP 
student spoke to at the outreach events, but there was no way to measure that outcome. 
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 The second goal of increasing the number of parents of adolescents who intended to 
vaccinate their adolescents against HPV and also increase the number of adolescents who 
intended to receive the HPV vaccine was also partially met. Results from the educational 
intervention with the students showed an increase in the overall number of adolescents who 
intend to get the HPV vaccine in the future. There was a 13% increase in intent in the 
adolescents from the pre-test to the post-test. There may have been an increase in parents to 
whom the DNP student spoke to at the outreach events who intended to vaccinate their 
adolescents against HPV, but again there was no way to measure that outcome. 
 The results demonstrated that students may be ready to act on a health decision as in the 
contstructs of the HBM. Students learned about their perceived susceptibility/severity of HPV 
with a 69% overall increase in students who stated that if they were infected with HPV, they 
could get genital warts and/or cancer. There was a 22% overall increase in students who stated 
there is a vaccine they could receive to prevent themselves from getting the most serious types of 
HPV, the perceived benefits. Students had 11% overall increase in those that reported there was 
someone they could talk to about their questions about HPV and the HPV vaccine, the perceived 
barriers. As mentioned above, there was a 13% overall increase in students who stated they 
intended to receive the HPV vaccine, which is their cue to action. The last step of the HBM is 
self-efficacy, which could not be captured in this project as there was no way to measure how 
many students actually received the HPV vaccine, but students and their parents now have tools 
to assist them in making an informed decision. 
 One unexpected finding in the results was the number of students who reported they had 
already received the HPV vaccine.. As mentioned above, this number should have remained the 
same in the post-test because no one received the vaccine while in health class, but the numbers 
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increased in those that reported they had already received the HPV vaccine on the post-test. The 
students were not given any information about HPV before the pre-test, so the DNP student 
surmises that the students did not know the vaccine by name, but when they heard it referred to 
as Gardasil or as the vaccine against cancer, many students realized they had in fact already 
received the vaccine. The post-test results also showed that the males and females reported the 
exact same vaccination rates, 33% stated they had received the HPV vaccine, 27% stated they 
had not, and 40% were unsure. These results do not match national data, which shows vaccine 
rates amongst males being much lower than amongst females. However, the reported vaccine 
rates were low overall, which does match the national data. As mentioned previously, the rate of 
HPV vaccination completion in females, ages 13-17 in Massachusetts is 48.5%, which is higher 
than the 33% of females in this group who reported they had been vaccinated. 
 The results from the students and the qualitative data from the parent outreach sessions 
match the findings of the literature review. Adolescents and their parents are not aware of HPV 
or its consequences and the HPV vaccine. This capstone project also demonstrated that schools 
with SBHCs are ideal locations to educate adolescents about HPV and the HPV vaccine. 
Students were excited to hear that the HPV vaccine was available at the Teen Clinic.  
 As mentioned previously, rates of cervical cancer are disproportionately higher in 
Hispanic and Black women. In this sample, out of the females who reported they had not been 
vaccinated against HPV or were unsure if they had been vaccinated, 70% were Hispanic, 8% 
Hispanic, more than once race, and 4% Black or African American. Also HPV-associated penile 
cancer is highest in Hispanic men. In this sample, out of the males who reported they had not 
been vaccinated against HPV or were unsure if they had been vaccinated, 59% were Hispanic 
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and 15% were Hispanic, more than one race. This demonstrates a need for adolescents, 
especially Hispanics and Blacks, to get vaccinated against HPV. 
 The study by Read et al. (2010) reported that 48.9% of females, ages 13-19, reported 
being sexually active by 14.9 years of age and over half of them had had more than one sexual 
partner. In this sample, amongst the adolescents who stated they had not received the HPV 
vaccine or were unsure if they had, 21% of them were 14 years of age, 62% 15 years of age, 16% 
16 years of age, and 1% 17 years of age. Though the students were not asked if they were 
sexually active, based on data from the Read et al. study, one can assume that some of these 
students are already sexually active and a large proportion of them are not vaccinated against 
HPV.  
Limitations/Recommendations 
 The findings of this capstone project should be interpreted in light of several limitations. 
First, not being able to secure a formal parent group to collect quantitative data from parents was 
a process failure, whereby part of the intended intervention was not able to be implemented (Issel, 
2009). Another barrier to conducting the parent group was the timeframe the DNP student had to 
implement this invention in order to comply with the academic requirements of the semester. If 
the DNP student had more time, perhaps the parent group could have been implemented. An 
additional limitation of this project was it relied on self-report. Self-report of data from 
adolescents may not be reliable (Burns & Grove, 2009). Another limitation of this project was 
the group being a convenience sample, which is a threat to the validity of the data (Burns & 
Grove, 2009). 
 Future projects within this population should focus on how to engage parents in the HPV 
vaccine decision-making for their children, but as evidenced by this project, it is difficult to find 
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a setting in which to conduct this type of intervention. Projects should also be implemented over 
a longer period of time and nurses should find a way to access health records of students to 
measure whether the rates of HPV vaccination actually increased after an educational 
intervention. Also future projects should have a comparison group, where one sample of students 
and parents receive an educational intervention versus a sample who do not get the intervention 
and HPV vaccination rates should be measured and compared.  
Conclusion/Future Implications 
 The results of this capstone project did show an increase in knowledge about HPV and 
the HPV vaccine and an increase in intent to vaccinate against HPV in adolescents. Schools, 
particularly those with SBHCs or vaccine clinics, are an opportune venue to teach adolescents 
about HPV and the HPV vaccine. The DNP student is hopeful that the health teachers will 
continue to teach HPV content in their health classes, as they were provided with the information 
to do so, and it could be done in the time of one class period. The student is also hopeful that the 
SBHCs in Holyoke High School and Dean Tech will continue to do outreach to adolescents and 
parents about the HPV vaccine, and as a result, HPV vaccination rates will increase over time. 
 This project is evidence that there is still a need for increased education targeting parents 
and adolescents about HPV and the HPV vaccine. Public health nurses and nurses who work in 
SBHCs are in an important position to do further research and evaluation about how to best reach 
this population and continue HPV vaccination efforts. Future projects and research about HPV 
and the HPV vaccine can lead to a more informed U.S. population, which should result in 
increased HPV vaccination rates and therefore, in fewer HPV-related cancer cases.  
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Appendix C 
HPV Fact Sheet 
 
What is HPV? 
HPV stands for human papillomavirus. HPV is a virus that is passed from one person to 
another by skin-to-skin sexual contact including vaginal, oral, and anal sex. HPV can cause 
genital warts or cell changes that can lead to cancer. 
 
More About HPV 
HPV is one of the most common sexually transmitted infections in the U.S. Almost all 
sexually active people will get HPV at some time in their lives, but most will never know it. 
74% of new HPV infections are in young people ages 15-24. Most of the time, the body 
naturally fights off HPV, but not always and it can lead to health problems. 
 
Does HPV Cause Cancer? 
Yes. HPV causes cancer in the cervix, vulva, and vagina in women and the penis in men. It 
causes cancer in the mouth/throat and anus in both men and women. Every year, HPV 
causes cancer in 18,000 women and 7,000 men in the U.S. 
 
How Do I Know if I Have HPV? 
Unless you have genital warts, most people do not have symptoms from HPV.  There is no 
routine test for HPV. For women, screening for cervical cancer is done with a Pap smear. 
 
Is There a Vaccine Available Against HPV? 
YES! The most common vaccine is Gardasil, which protects people from the 4 most 
common strains of HPV that cause genital warts and cancer. The vaccine is 3 shots, given 
over a period of 6 months. 
 
Who Should Get the HPV Vaccine? Where Can I Get the Vaccine? 
All boys and girls ages 9 to 26 should get the HPV vaccine.  
You must have your parent/guardian’s permission to get the vaccine. It is available at the 
Teen Clinic or at your doctor’s office. 
 
Is the HPV Vaccine Safe? 
YES! 46 million doses have been given around the world and 
there have been no serious concerns. Some people report mild 
side effects like pain in their arm, fever, dizziness, and nausea. 
 
How Can I Protect Myself Against HPV?                          
Get the HPV vaccine. 
Practice abstinence.  
Use condoms every time you have sex.  
Limit the amount of sexual partners you have. 
 
* Info adapted from CDC.gov 
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Appendix D 
 
Participant #_____ 
 
Demographic Information 
 
Circle the best answer or fill in the blank for all of the following questions. 
 
Example: 
The current President of the United States is Barack Obama. 
 
True           or          False 
 
 
1. I am: 
 
Female          Male          Other (Transgender) 
 
2. How old are you? 
 
__________ 
 
 
3. I am: 
 
Hispanic  
White 
African American/Black     
Asian  
Native American      
Native Hawaiian/Pacific Islander      
Multi-Race, Non-Hispanic 
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Participant #_____ 
Pretest   
 
Circle the best answer or fill in the blank for all of the following questions. 
 
Example: The current President of the United States is Barack Obama. 
 
True           or          False 
 
1. If I am infected with human papillomavirus (HPV), I could get genital warts and/or cancer.       
 
Agree         Disagree          Unsure 
 
2. HPV is one of the most common sexually transmitted infections in the United States.      
 
True          or          False 
 
3. The highest rates of new genital HPV infections occur in young adults between the ages of 15-24.       
 
True          or          False 
 
4. How is HPV transmitted? Select all the correct answers.       
A. Skin-to-skin contact 
B. Contact with infected blood 
C. An infected person coughs or sneezes on another person 
D. Vaginal, anal, or oral sex 
 
5. Who should receive the HPV vaccine?       
 
Girls only          Boys only          Both girls and boys 
 
6. Have you received the HPV vaccine? 
 
Yes          No          Unsure 
 
If you answered yes to question # 6, do not answer any more questions 
 
7. I believe I could be at risk (now or in the future) for getting HPV.     
 
Agree          Disagree          Unsure 
 
8. There is a vaccine I could receive to prevent myself from getting the most serious types of HPV?       
 
Agree          Disagree          Unsure                       
 
9. There is someone I could talk to (parent, nurse, doctor, friend, teacher) about my questions and 
concerns about HPV and the HPV vaccine.       
 
Agree          Disagree          Unsure 
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10. If you have not received the HPV vaccine, do you intend to get the HPV vaccine in the future?        
 
Yes          No          Unsure            
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Appendix E 
Postest                                                                            Participant #_____ 
 
Circle the best answer or fill in the blank for all of the following questions. 
 
Example: The current President of the United States is Barack Obama. 
 
True           or          False 
 
1. If I am infected with human papillomavirus (HPV), I could get genital warts and/or cancer.      
 
Agree         Disagree          Unsure 
 
2. HPV is one of the most common sexually transmitted infections in the United States.       
 
True          or          False 
 
3. The highest rates of new genital HPV infections occur in young adults between the ages of 15-24.       
 
True          or          False 
 
4. How is HPV transmitted? Select all the correct answers.       
A. Skin-to-skin contact 
B. Contact with infected blood 
C. An infected person coughs or sneezes on another person 
D. Vaginal, anal, or oral sex 
 
5. Who should receive the HPV vaccine?       
 
Girls only          Boys only          Both girls and boys 
 
6. Have you received the HPV vaccine? 
 
Yes          No          Unsure 
 
If you answered yes to question # 6, do not answer any more questions 
 
7. I believe I could be at risk (now or in the future) for getting HPV.     
 
Agree          Disagree          Unsure 
 
8. There is a vaccine I could receive to prevent myself from getting the most serious types of HPV?       
 
Agree          Disagree          Unsure                  
 
9. There is someone I could talk to (parent, nurse, doctor, friend, teacher) about my questions and 
concerns about HPV and the HPV vaccine.       
 
Agree          Disagree          Unsure 
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10. If you have not received the HPV vaccine, do you intend to get the HPV vaccine in the future?        
 
Yes          No          Unsure            
Thank you for your time and participation. 
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Appendix F 
Participant #_____ 
 
Demographic Information 
 
Circle the best answer or fill in the blank for all of the following questions. 
 
Example: 
The current President of the United States is Barack Obama. 
 
True           or          False 
 
1. I am the parent/guardian of a child entering the 9th grade next year. 
 
Yes          or          No 
 
If you answered No, you do not need to answer any more questions. 
 
2. My child is: 
 
Male          Female          Other (Transgender)            
 
3. The current age of my child is: 
 
________________ 
 
4. I am: 
 
Male          Female         Other (Transgender) 
 
5. I am: 
 
Hispanic  
White 
African American/Black     
Asian  
Native American      
Native Hawaiian/Pacific Islander      
Multi-Race, Non-Hispanic 
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Pretest                                                                        Participant #_____ 
 
Circle the best answer or fill in the blank for all of the following questions. 
 
Example: The current President of the United States is Barack Obama. 
 
True           or          False 
 
1. How is human papilloma virus (HPV) transmitted? Select all the correct answers.       
A. Skin-to-skin contact 
B. Contact with infected blood 
C. An infected person coughs or sneezes on another person 
D. Vaginal, anal, or oral sex 
 
2. Who should receive the HPV vaccine?       
 
Girls only          Boys only          Both girls and boys 
 
3. Has your adolescent child received the HPV vaccine?  
Yes          No          Unsure 
 
If you answered yes to question #3, do not answer any more questions 
 
4. I believe my adolescent child could be at risk (now or in the future) for getting HPV.  
Agree          Disagree          Unsure 
 
5. My adolescent child could get genital warts and/or cancer someday if he/she does not receive the 
HPV vaccine.       
 
Agree          Disagree          Unsure 
 
6. There is a vaccine my adolescent child could receive to prevent him/her from getting the most 
serious types of HPV.       
 
Agree          Disagree           Unsure                      
 
7. The HPV vaccine is safe for my adolescent child.   
 
Agree          Disagree          Unsure 
 
8. My adolescent child should receive the HPV vaccine if his/her healthcare provider recommends it. 
 
Agree          Disagree          Unsure 
 
9. I have access to all the information I need to make a good decision about having my adolescent 
child receiving the HPV vaccine.    
 
Yes          No          Unsure            
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10. If your adolescent child has not received the HPV vaccine, do you intend to have him/her get the 
HPV vaccine in the future?        
 
Yes          No          Unsure            
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Appendix G 
Posttest                                                                         Participant #_____ 
 
Circle the best answer or fill in the blank for all of the following questions. 
Example: The current President of the United States is Barack Obama. 
 
True           or          False 
 
1. How is human papilloma virus (HPV) transmitted? Select all the correct answers.       
A. Skin-to-skin contact 
B. Contact with infected blood 
C. An infected person coughs or sneezes on another person 
D. Vaginal, anal, or oral sex 
 
2. Who should receive the HPV vaccine?       
 
Girls only          Boys only          Both girls and boys 
 
3. Has your adolescent child received the HPV vaccine?  
Yes          No          Unsure 
 
If you answered yes to question #3, do not answer any more questions 
 
4. I believe my adolescent child could be at risk (now or in the future) for getting HPV  
Agree          Disagree          Unsure 
 
5. My adolescent child could get genital warts and/or cancer someday if he/she does not receive the 
HPV vaccine.       
 
Agree          Disagree          Unsure 
 
6. There is a vaccine my adolescent child could receive to prevent him/her from getting the most 
serious types of HPV.       
 
Agree          Disagree           Unsure                      
 
7. The HPV vaccine is safe for my adolescent child.   
 
Agree          Disagree          Unsure 
 
8. My adolescent child should receive the HPV vaccine if his/her healthcare provider recommends it. 
 
Agree          Disagree          Unsure 
 
9. I have access to all the information I need to make a good decision about having my adolescent 
child receiving the HPV vaccine.    
 
Yes          No          Unsure            
 
INCREASING HPV VACCINATION RATES 67 
10. If your adolescent child has not received the HPV vaccine, do you intend to have him/her get the 
HPV vaccine in the future?        
 
Yes          No          Unsure            
Thank you for your time and participation. 
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Appendix H 
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Appendix I 
ATTENTION PARENTS! 
 
The HPV vaccine is available at the Teen Clinic at Dean Tech or is available at your 
pediatrician’s office. 
 
If you would like to schedule an appointment for your adolescent to receive the HPV 
vaccine at the Teen Clinic, please have your son or daughter come in to the Teen Clinic and 
pick up a permission slip. 
 
¡ATENCION PADRES! 
 
La vacuna contra el VPH está disponible en la Clínica de Adolescentes en Holyoke High 
School y también está disponible en el consultorio de su pediatra. 
 
 Si usted desea hacer una cita para su hijo/a para recibir la vacuna contra el VPH en la 
Clínica de Adolescentes, por favor dígale a su hijo/a que se presenten a la Clínica de 
Adolescentes para recoger una hoja de permiso. 
